DDInter1268 DDInter150
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA. Natalizumab was approved by the European Commission on September 22, 2023.
Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection. Azathiprine was granted FDA approval on 20 March 1968.
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Tioguanine
Tioguanine {u} (Compound) resembles {v} (Compound) Adenine
Adenine {u} (Compound) resembles {v} (Compound) Azathioprine
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Tioguanine
Tioguanine {u} (Compound) binds {v} (Gene) HPRT1
HPRT1 {u} (Gene) is bound by {v} (Compound) Azathioprine
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) treats {v} (Disease) systemic lupus erythematosus
systemic lupus erythematosus {u} (Disease) is treated by {v} (Compound) Azathioprine
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Tioguanine
Tioguanine {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Azathioprine
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) downregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Azathioprine
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) upregulates {v} (Gene) GTPBP8
GTPBP8 {u} (Gene) is upregulated by {v} (Compound) Azathioprine
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Mycophenolate mofetil
Mycophenolate mofetil {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is downregulated by {v} (Compound) Azathioprine
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Betamethasone
Betamethasone {u} (Compound) upregulates {v} (Gene) MRPL12
MRPL12 {u} (Gene) is downregulated by {v} (Compound) Azathioprine
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Ponatinib
Ponatinib {u} (Compound) downregulates {v} (Gene) HPRT1
HPRT1 {u} (Gene) is bound by {v} (Compound) Azathioprine
Natalizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) binds {v} (Gene) GSTA2
GSTA2 {u} (Gene) is bound by {v} (Compound) Azathioprine
Natalizumab may lead to a major life threatening interaction when taken with Tioguanine and Tioguanine (Compound) resembles Adenine (Compound) and Adenine (Compound) resembles Azathioprine (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Tioguanine and Tioguanine (Compound) binds HPRT1 (Gene) and HPRT1 (Gene) is bound by Azathioprine (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) treats systemic lupus erythematosus (Disease) and systemic lupus erythematosus (Disease) is treated by Azathioprine (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Tioguanine and Tioguanine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Azathioprine (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) downregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Azathioprine (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) upregulates GTPBP8 (Gene) and GTPBP8 (Gene) is upregulated by Azathioprine (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is downregulated by Azathioprine (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Betamethasone and Betamethasone (Compound) upregulates MRPL12 (Gene) and MRPL12 (Gene) is downregulated by Azathioprine (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib (Compound) downregulates HPRT1 (Gene) and HPRT1 (Gene) is bound by Azathioprine (Compound)
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) binds GSTA2 (Gene) and GSTA2 (Gene) is bound by Azathioprine (Compound)